SMFR SEMA4 HLDGS CORP

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, , Chief Executive Officer of Sema4, and , Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time.

Conference Call Details

Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast of the event will be available on the “Events” section of the Sema4 investor relations website at .

About Sema4

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all. For more information, please visit  and connect with us on , , , and .

Investor Relations Contact:

Joel Kaufman

Sema4

Media Contact:

Radley Moss

Sema4



EN
04/11/2022

Underlying

SMFRSEMA4 HLDGS CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEMA4 HLDGS CORP

 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, Jul...

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024  STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024. Management will host a conference call that day to discuss second quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.  Conference Call Details Investors interested in listening to the conference call are required ...

July 11, 2024 1 EN
 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapi...

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients -- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) -- STAMFORD, Conn., June 10, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insig...

June 10, 2024 1 EN
 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx Announces Patient Access Program to Expand Access to Exome Test...

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access to exome sequencing for pediatric epilepsy patients. “Receiving a genetic diagnosis can be critical in a child’s journey toward effective treatment and care, and we are thrilled our biopha...

June 5, 2024 1 EN
 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx to Participate in Upcoming Investor Conferences

GeneDx to Participate in Upcoming Investor Conferences STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in two upcoming investor conferences in June: Jefferies Healthcare Conference - New York City, New York Fireside chat on Wednesday, June 5 at 9:00 a.m. ET44th Annual Goldman Sachs Global Healthcare Conference - Miami, Florida Fireside chat on Monday, June 10 at 3:20 p.m. ET Live and archived webcasts of the presentation will be avail...

May 22, 2024 1 EN
 PRESS RELEASE
Free
SMFR SEMA4 HLDGS COR...

GeneDx Reports First Quarter 2024 Financial Results and Business Highl...

GeneDx Reports First Quarter 2024 Financial Results and Business Highlights Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss2 to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMF...

April 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch